The FDA cleared Cytokinetics’ aficamten (Myqorzo) tablets for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), providing a daily oral therapy to improve functional capacity and symptoms. The approval positions Cytokinetics as a direct competitor to Bristol Myers Squibb’s Camzyos and introduces a myosin inhibitor with a different safety-monitoring profile. Market analysts note Myqorzo’s less restrictive monitoring requirements may accelerate outpatient prescribing compared with Camzyos, but labeling includes a boxed warning for heart-failure risk tied to reduced left ventricular ejection fraction. Investors reacted positively, and the approval creates a new commercial front in oHCM where demand for oral, disease-modifying myosin inhibitors is rising.